Consumption of a high-fat diet abrogates inhibitory effects of methylseleninic acid on spontaneous metastasis of Lewis lung carcinoma in mice

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2308-2313

  Yan, Lin ^a   Combs, Gerald F ^a  

^a GRAND FORKS HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; CORN OIL; GELATINASE B; LEPTIN; METHYLSELENINIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SELENIUM DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; METHYLSELENIC ACID; ORGANOSELENIUM DERIVATIVE; PROTEASE NEXIN I; SERPINE2 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; CALORIC INTAKE; CANCER SURGERY; CONTROLLED STUDY; DIET SUPPLEMENTATION; FAT INTAKE; LEWIS CARCINOMA; LEWIS LUNG CARCINOMA CELL; LIPID DIET; LOW FAT DIET; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR VOLUME; ADVERSE EFFECTS; ANIMAL; BLOOD; C57BL MOUSE; CARCINOMA, LEWIS LUNG; DRUG EFFECTS; PATHOLOGY;

ANIMALS; ANTICARCINOGENIC AGENTS; BODY COMPOSITION; CARCINOMA, LEWIS LUNG; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; LEPTIN; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; ORGANOSELENIUM COMPOUNDS; SERPIN E2; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908676495     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu153     Document Type: Article

References (50)

1. Kryukov,G.V. et al. (2004) The prokaryotic selenoproteome. EMBO Rep., 5, 538-543.
2. Dennert,G. et al. (2011) Selenium for preventing cancer. Cochrane Database of Systematic Reviews.
3. Yamanoshita,O. et al. (2007) Chemopreventive effect of seleniumenriched Japanese radish sprout against breast cancer induced by 7,12-dimethylbenz[a]anthracene in rats. Tohoku J. Exp. Med., 212, 191-198.
4. Bhattacharyya,R.S. et al. (2008) Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 72, 935-940.
5. Li,G.X. et al. (2008) Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis, 29, 1005-1012.
6. Lippman,S.M. et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 301, 39-51.
7. Clark,L.C. et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA, 276, 1957-1963.
8. Rayman,M.P. et al. (2009) Selenium and vitamin E supplementation for cancer prevention. JAMA, 301, 1876; author reply 1877.
9. Suzuki,K.T. et al. (2006) Metabolic transformation of methylseleninic acid through key selenium intermediate selenide. Toxicol. Appl. Pharmacol., 215, 189-197.
10. Combs,G.F. Jr et al. (2001) An analysis of cancer prevention by selenium. BioFactors, 14, 153-159.
11. Ip,C. et al. (1991) Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res., 51, 595-600.
12. Yan,L. et al. (2012) Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice. Int. J. Cancer, 131, 1260-1266.
13. Wrobel,J.K. et al. (2013) Supplementation with selenium-enriched yeast attenuates brain metastatic growth. Nutr. Cancer, 65, 563-570.
14. Yazdi,M.H. et al. (2013) Selenium nanoparticle-enriched Lactobacillus brevis causes more efficient immune responses in vivo and reduces the liver metastasis in metastatic form of mouse breast cancer. DARU J Pharmaceutical Sci., 21, 33.
15. Bianchini,F. et al. (2002) Overweight, obesity, and cancer risk. Lancet Oncol., 3, 565-574.
16. Senie,R.T. et al. (1992) Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann. Intern. Med., 116, 26-32.
17. Hebert,J.R. et al. (1988) Weight, height and body mass index in the prognosis of breast cancer: early results of a prospective study. Int. J. Cancer, 42, 315-318.
18. Daniell, H.W. (1988) Increased lymph node metastases at mastectomy for breast cancer associated with host obesity, cigarette smoking, age, and large tumor size. Cancer, 62, 429-435.
19. Gong,Z. et al. (2007) Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer, 109, 1192-1202.
20. Loi,S. et al. (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol. Biomarkers Prev., 14, 1686-1691.
21. Mori,A. et al. (2006) Severe pulmonary metastasis in obese and diabetic mice. Int. J. Cancer, 119, 2760-2767.
22. Yan,L. et al. (2010) Effects of dietary fat on spontaneous metastasis of Lewis lung carcinoma in mice. Clin. Exp. Metastasis, 27, 581-590.
23. Institute for Laboratory Animal Research (2011) Guide for the Care and Use of Laboratory Animals. National Academies Press, Washington, DC.
24. Reeves,P.G. et al. (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr., 123, 1939-1951.
25. Corn Refiners Association (2006) Corn Oil. http://www.corn.org/wp-content/ uploads/2009/12/CornOil.pdf. pp. 1-22.
26. Welch,D.R. et al. (1983) Comparison of 'spontaneous' and 'experimental' metastasis using rat 13762 mammary adenocarcinoma metastatic cell clones. Invasion Metastasis, 3, 65-80.
27. Kryukov,G.V. et al. (2003) Characterization of mammalian selenoproteomes. Science, 300, 1439-1443.
28. Duffy,M.J. et al. (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer, 62, 531-533.
29. Nikkola,J. et al. (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin. Cancer Res., 11, 5158-5166.
30. Seki,T. et al. (2001) Reciprocal regulation of tissue-type and urokinasetype plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes. J. Cell. Physiol., 189, 72-78.
31. Bouloumie,A. et al. (2001) Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes, 50, 2080-2086.
32. Yan,L. et al. (2013) Effects of voluntary running and soy supplementation on diet-induced metabolic disturbance and inflammation in mice. J. Agric. Food Chem., 61, 9373-9379.
33. Czekay,R.P. et al. (2004) Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp. Biol. Med. (Maywood)., 229, 1090-1096.
34. Seetoo,D.Q. et al. (2003) Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J. Surg. Oncol., 82, 184-193.
35. Ueno,T. et al. (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res., 6, 3282-3289.
36. Chavey,C. et al. (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res., 9, R15.
37. Ferrajoli,A. et al. (2002) The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood, 100, 1215-1219.
38. Guo,R.P. et al. (2006) Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 132, 547-555.
39. Ree,A.H. et al. (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res., 3, 1623-1628.
40. McMahon,G.A. et al. (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem., 276, 33964-33968.
41. Kimura,Y. et al. (2007) High-fat, high-sucrose, and high-cholesterol diets accelerate tumor growth and metastasis in tumor-bearing mice. Nutr. Cancer, 59, 207-216.
42. Okahara,H. et al. (1994) Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res., 54, 3233-3236.
43. Achbarou,A. et al. (1994) Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res., 54, 2372-2377.
44. Kido,A. et al. (1999) Overexpression of matrix metalloproteinase (MMP)-9 correlates with metastatic potency of spontaneous and 4-hydroxyaminoquinoline 1-oxide (4-HAQO)-induced transplantable osteosarcomas in rats. Cancer Lett., 137, 209-216.
45. Kopitz,C. et al. (2007) Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res., 67, 8615-8623.
46. Blakley, B.R. (1987) Alterations in urethan-induced adenoma formation in mice exposed to selenium and arsenic. Drug Nutr. Interact, 5, 97-102.
47. Barcelo-Coblijn,G. et al. (2009) Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels. Prog. Lipid Res., 48, 355-374.
48. Gerber, M. (2012) Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br. J. Nutr., 107 (suppl. 2), S228-S239.
49. Algamas-Dimantov,A. et al. (2012) Amelioration of diabesity-induced colorectal ontogenesis by omega-3 fatty acids in mice. J. Lipid Res., 53, 1056-1070.
50. Wang,Y. et al. (2007) The obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol. Rev., 29, 6-28.